Virax Biolabs Group Ltd income statement

In fiscal 2026, Virax Biolabs Group Ltd reported revenue of $12,423, up 96.2% on the year before, operating income of −$6.4m (a -51515.2% margin) and net income of −$5.0m, or −$12.64 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Virax Biolabs Group Ltd: income statement, annual
Fiscal year	2021Mar 2021	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Revenue	124	0	9	156	6	12
Cost of revenue	133	—	10	106	59	5
Gross profit	−9	—	−1	51	−53	8
Research and development	120	434	2,179	1,615	2,031	3,738
Operating income	−645	−1,734	−5,733	−6,526	−6,077	−6,400
Interest expense	—	—	0	26	57	60
Income before tax	−673	−1,750	−5,458	−6,739	−6,204	−5,932
Income tax	—	—	—	0	−137	−900
Net income	−651	−1,709	−5,457	−6,734	−6,061	−5,024
Diluted EPS	—	−$22.38	−$64.13	−$83.90	−$40.62	−$12.64
Diluted shares (average)	—	—	—	—	—	—
EBITDA	—	−1,734	−5,733	−6,471	−5,810	−6,039

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: LYEL vs VRAX CELZ vs VRAX AIM vs VRAX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Virax Biolabs Group Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Virax Biolabs Group Ltd.